Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

("EKF" or "the Company")

AGM Statement

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, will hold its Annual General Meeting today at 2pm at the offices of Canaccord Genuity Limited, 41 Lothbury, London EC2R 7AE.

At the meeting David Evans, Executive Chairman of EKF, will provide shareholders with the following update:

Trading in the period to date continues to be in line with expectations and I anticipate seeing further advancement across all areas of our business as we continue to execute against an ambitious growth plan for 2013.

In March 2013 we established our Molecular Diagnostics division to offer innovative products with the potential to change current DNA extraction and detection practices, enabling us to address the fast growing companion diagnostics market.

Our Pointman™ technology provides a reliable and highly sensitive determination of the presence or absence of a point mutation, a random mutation that occurs at one point in the DNA sequence. We were recently granted patents in both Europe and Japan for this technology and we were delighted to announce earlier this week the launch of our first PointMan™ DNA enrichment products for the Research Use Only market ahead of plan.

We are very excited about the prospects for our PointMan™ technology combined with the extraction technology covered by our Arcis Biotechnology Holdings Limited licence, and we believe we are well placed to achieve a leading position in the companion diagnostics market.

We remain confident in delivering growth for 2013, during a year that will see a full year of Quo-Lab sales contribution as well as HemoPoint H2 sales through Alere in North America.

Enquiries:

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2. 

On the 4 March 2013, EKF announced the establishment of EKF Molecular Diagnostics Ltd to offer innovative products with the potential to change current DNA extraction and detection practices, enabling EKF to address the fast growing companion diagnostics market.

For more information please visit the website: www.ekfdiagnostics.com